缅北禁地

Introduction

Herbie Newell is Professor of Cancer Therapeutics. He has over 40 years experience of the discovery and development of conventional and novel cancer chemotherapies.

Roles and Responsibilities

Professor of Cancer Therapeutics
Northern Institute for Cancer Research

Qualifications

1979 Institute of Biology - Membership by examination in Pharmacology

1984 University of London - PhD Pharmacology

2011 Academy of Medical Sciences - Fellow

Previous Positions

2009-Date 缅北禁地 Cancer Centre, Northern Institute for Cancer Research, 缅北禁地, 缅北禁地 upon Tyne, Professor of Cancer Therapeutics

2006-2009 Cancer Research UK, London, Interim Executive Director of Clinical and Translational Research and Director of Translational Research (0.6 FTE)

2003-2006 Northern Institute for Cancer Research, University of 缅北禁地, 缅北禁地 upon Tyne, Scientific Director and Professor of Cancer Therapeutics

1995-2003 Cancer Research Unit, University of 缅北禁地, 缅北禁地 upon Tyne, Associate and Acting Director, Professor of Cancer Therapeutics

1989-1995 Cancer Research Unit, University of 缅北禁地, 缅北禁地 upon Tyne, Senior Lecturer

1988-1989 Clinical Pharmacology Team, Drug Development Section, Institute of Cancer Research, Sutton, Surrey, Grade 1 Scientist

1984-1988 Department of Biochemical Pharmacology, Institute of Cancer Research, Sutton, Surrey, Grade 2 Scientist

1976-1984 Department of Biochemical Pharmacology, Institute of Cancer Research, Sutton, Surrey, Research Officer

Memberships

Past - Chair and Member of numerous CR UK, NCRI, EORTC, UK and non-UK University and Government Institute review committees

Past - HEFCE RAE 2008 UoA 2 (Cancer Studies) Panel Member

Past - HEFCE RAE 2001 UoA 9 (Pharmacy) Panel Member

Current - Chair MRC DPFS/DCS Panel

Current – Chair CRT Pioneer Fund Scientific Advisory Board        

Current - Chair NIHR Manchester Musculoskeletal BRU Scientific Advisory Board

Current – Chair Ontario Institute for Cancer Research High Impact Clinical Trials Program Scientific Advisory Board

Member – CRT Discovery Laboratory Scientific Advisory Board

Member - IMI QuIC-ConCePT Scientific Advisory Board

Member - British Association for Cancer Research

Member - American Association for Cancer Research

Languages

English

Research Interests

Cancer pharmacology
Drug development
Pharmacokinetics of anticancer drugs
DNA repair modulation
Kinase inhibitors

Other Expertise

Translational cancer research
Early clinical trials in cancer

Current Work

The development of inhibitors of:
Cyclin dependent kinases
DNA damage related kinases
Receptor tyrosine kinases
DNA repair enzymes and proteins
Pharmacologically-guided dosing in adults and children

Future Research

The development of:
Selective antitumour agents
Non-invasive imaging methodology for pharmacokinetic and pharmacodynamic studies

Research Roles

Professor of Cancer Therapeutics
Northern Institute for Cancer Research

Postgraduate Supervision

PhD Student Supervisor

Esteem Indicators

2004 Michel Clavel Award Lecturer at the 16th EORTC/NCI/AACR New Drugs Conference, Geneva

Funding

"缅北禁地 Paediatric Pharmacology UKCCSG - CRC Site Visit" Cancer Research Campaign. Jan 2000 - Jan 2004. £71,130 per annum. Held with AV Boddy and ADJ Pearson.

"Synthesis and evaluation of novel inhibitors of DNA-dependent protein kinase (DNA-PK)" BBSRC Industrial CASE studentship with KuDOS Pharmaceuticals. Oct 2000 - Oct 2003. £54,210. Held with AH Calvert, NJ Curtin, BT Golding and RJ Griffin.

"Combinatorial synthesis of libraries of small molecule modulators of signal transduction pathways" EPSRC quota studentship. Oct 2000 - Oct 2003. £40,000. Held with (PI) AH Calvert, NJ Curtin, BT Golding, RJ Griffin and I Hardcastle.

"Potentiation of thymidylate synthase inhibition by tumour-specific thymidine depletion" Cancer Research Campaign. Oct 2000 - Oct 2003. £44,461. Held with AV Boddy and GA Taylor.

"Design and synthesis of selective DNA-dependent protein kinase (DNA-PK) inhibitors" Cancer Research Campaign. Oct 2001 - Oct 2004. £64,000. Held with AH Calvert, NJ Curtin, BT Golding, RJ Griffin and IR Hardcastle.

"The synthesis of DNA-dependent protein kinase inhibitors" KuDOS pharmaceuticals. Equipment grant, 2001. £62,000. Held with AH Calvert, NJ Curtin, BT Golding RJ Griffin and IR Harcastle.

"Development of pharmacodynamic assays for the clinical evaluation of novel PARP inhibitors, and pre-clinical investigations of backup compounds" Agouron Pfizer GRD. Jan 2001-Jan 2002. £107,500. Held with AV Boddy, NJ Curtin, AH Calvert and BW Durkacz.

"Clerical support in recognition of contributions to CRC Committees" Cancer Research Campaign. Sept 2000 - Date. £14,818 per annum.

"Molecular Mechanisms of Disease Progression and Novel Treatments for Prostate Cancer" NCRI/MRC. Oct 2001 - Oct 2006. £1,627,389. Held with IR Hardcastle, HY Leung, DE Neal and CN Robson.

"Design, synthesis and evaluation of novel CDK inhibitors" AstraZeneca Pharmaceuticals. 2002-2004. £100,000. Held with AH Calvert, NJ Curtin, RJ Griffin, BT Golding and IR Hardcastle.:

"Preclinical and pharmacodynamic studies with novel DNA-PK inhibitors" KuDos Pharmaceuticals. Jan 2002 - Jan 2004. £183,394. Held with AH Calvert, NJ Curtin, BW Durkacz, BT Golding RJ Griffin and IR Hardcastle.

"Cancer Research UK Developmental Therapeutics Programme" Joint Director with AH Calvert. Oct 2002 - Sept 2007. £1,000,000 per annum.

"Establishment of 缅北禁地 as a National Translational Cancer Research Network (NTRAC) Centre. Department of Health. Held with AV Boddy, AH Calvert, A Chippendale, HY Leung, D Ellison, M Verrill. June 2003 - May 2008. £1,080,000.

Industrial Relevance

Member of Scientific Advisory Panels for:
Astex Technology, AstraZenenca, Eisia Pharmaceuticals, OSI Pharmaceuticals, Viscum AG, Xenova

Patents

JONES T.R., JACKMAN A.L. and NEWELL D.R. (1986): Anticancer quinazoline derivatives. UK and Foreign Patent No. 8513754.

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R., AND GOLDING, B. T. Benzamide Analogues ADPRT (PARP) Inhibitors Patent Application Number PCT/GB95/00513

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R. AND GOLDING, B. T. Benzimidazole PARP Inhibitors. Patent Application Number PCT/GB96/01832.

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R. AND GOLDING, B. T. Prodrugs of PARP Inhibitors. Patent Application Number 9702701.5

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R. AND GOLDING, B. T. Pyrimidopyrimidine Compounds. Patent Application Number 9706618.7.

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R. AND GOLDING, B. T., ENDICOTT, J.A., NOBLE, M.E.M., BOYLE, F.T. AND JEWSBURY, P.J. Purine CDK Inhibitors. Patent Application Number 9714603.9

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R. AND GOLDING, B. T. ENDICOTT, J.A., NOBLE, M.E.M., BOYLE, F.T. AND JEWSBURY, P.J. Pyrimidine CDK Inhibitors. Patent Application Number 9806739.0

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R. AND GOLDING, B. T. Dipyridamole analogues. Patent Application Number PCT/GB98/00966

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R. AND GOLDING, B. T. Anilinopurine CDK inhibitors. Patent Application Number PCT/GB01/101686.4

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R., GOLDING, B. T. HARDCASTLE, I.R., MARTIN, N., SMITH, G.C.M., RAYNAUD, F. AND WORKMAN, P. DNA-PK inhibitors - 1. Patent Application Number PCT/GB01/19865.4

GRIFFIN, R. J., CALVERT, A. H., CURTIN, N. J., NEWELL, D. R., GOLDING, B. T. HARDCASTLE, I.R., MARTIN, N., SMITH, G.C.M., RAYNAUD, F. AND WORKMAN, P. DNA-PK inhibitors - 2. Patent Application Number PCT/GB01/19863.9

WALLING, J.M., WEBB, H.K., CALVERT, A.H. AND NEWELL, D.R. Lometrexol combination therapy. Patent Application Number 10/010,740.

• Coffey K, Blackburn TJ, Cook S, Golding BT, Griffin RJ, Hardcastle IR, Hewitt L, Huberman K, McNeill HV, Newell DR, Roche C, Ryan-Munden CA, Watson A, Robson CN. . PLoS One 2012, 7(10), e45539.
• Munck JM, Batey MA, Zhao Y, Jenkins H, Richardson C, Cano C, Tavecchio M, Barbeau J, Bardos J, Cornell L, Griffin RJ, Menear KA, Slade A, Thommes P, Martin NMB, Newell DR, Smith GCM, Curtin NJ. . Molecular Cancer Therapeutics 2012, 11(8), 1789-1798.
• Tavecchio M, Munck JM, Cano C, Newell DR, Curtin NJ. . Cancer Chemotherapy and Pharmacology 2012, 69(1), 155-164.
• Alhasan SF, Beale GS, Newell DR, Reeves HL. . In: Digestive Disorders Federation Meeting. 2012, Liverpool, UK: BMJ Group.
• Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR. . British Journal of Cancer 2012, 106(8), 1386-1394.
• de Brito LR, Batey MA, Zhao Y, Squires MS, Maitland H, Leung HY, Hall AG, Jackson G, Newell DR, Irving JAE. . Leukemia Research 2011, 35(9), 1233-1240.
• Johnson N, Li YC, Walton ZE, Cheng KA, Li DA, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D'Andrea AD, Curtin NJ, Wong KK, Shapiro GI. . Nature Medicine 2011, 17(7), 875-882.
• Hardcastle IR, Liu J, Valeur E, Watson A, Ahmed SU, Blackburn TJ, Bennaceur K, Clegg W, Drummond C, Endicott JA, Golding BT, Griffin RJ, Gruber J, Haggerty K, Harrington RW, Hutton C, Kemp S, Lu X, McDonnell JM, Newell DR, Noble ME, Payne SL, Revill CH, Riedinger C, Xu Q, Lunec J. . Journal of Medicinal Chemistry 2011, 54(5), 1233-1243.
• Watson AF, Liu JF, Bennaceur K, Drummond CJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Lu XH, McDonnell JM, Newell DR, Noble MEM, Revill CH, Riedinger C, Xu Q, Zhao Y, Lunec J, Hardcastle IR. . Bioorganic & Medicinal Chemistry Letters 2011, 21(19), 5916-5919.
• Saravanan K, Barlow HC, Barton M, Calvert AH, Golding BT, Newell DR, Northen JS, Curtin NJ, Thomas HD, Griffin RJ. . Journal of Medicinal Chemistry 2011, 54(6), 1847-1859.
• Squires M, Ward G, Saxty G, Berdini V, Cleasby A, King P, Angibaud P, Perera T, Fazal L, Ross D, Jones CG, Madin A, Benning RK, Vickerstaffe E, O'Brien A, Frederickson M, Reader M, Hamlett C, Batey MA, Rich S, Carr M, Miller D, Feltell R, Thiru A, Bethell S, Devine LA, Graham BL, Pike A, Cosme J, Lewis EJ, Freyne E, Lyons J, Irving J, Murray C, Newell DR, Thompson NT. . Molecular Cancer Therapeutics 2011, 10(9), 1542-1552.
• Thomas HD, Wang LZ, Roche C, Bentley J, Cheng YZ, Hardcastle IR, Golding BT, Griffin RJ, Curtin NJ, Newell DR. . European Journal of Cancer 2011, 47(13), 2052-2059.
• Pridgeon SW, Heer R, Taylor GA, Newell DR, O'Toole K, Robinson M, Xu YZ, Karran P, Boddy AV. . British Journal of Cancer 2011, 104(12), 1869-1876.
• Meschini E, Endicott JA, Golding BT, Hardcastle IR, Newell DR, Noble MEM, Wang LZ, Griffin RJ. . In: Abstracts of Papers of the American Chemical Society. 2010, American Chemical Society.
• Clapham KM, Rennison T, Rodriguez-Aristegui S, Bardos J, Curtin NJ, Golding BT, Hardcastle IR, Newell DR, Cano C, Griffin RJ. . In: EJC Supplements: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2010, Berlin, Germany: Pergamon.
• Cano C, Barbeau OR, Bailey C, Cockcroft XL, Curtin NJ, Duggan H, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Knights C, Menear KA, Newell DR, Richardson CJ, Smith GC, Spittle B, Griffin RJ. . Journal of Medicinal Chemistry 2010, 53(24), 8498-8507.
• Carbain B, Roche C, Endicott JA, Golding BT, Hardcastle IR, Cano C, Zhen-Wang L, Newell DR, Noble MEM, Griffin RJ. . In: European Journal of Cancer Supplements: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2010, Berlin: Elsevier.
• Cornell L, Munck JM, Budhisetiawan F, Newell DR, Bardos JI, Manas D, Curtin NJ, Reeves H. . In: 61st Annual Meeting of the American Association for the Study of Liver Diseases. 2010, Boston, MA: Hepatology: Wiley-Blackwell.
• Watson AF, Golding BT, Griffin RJ, Hutton C, Liu JF, Lug XH, Lunec J, Newell DR, Valeur E, Hardcastle IR. . In: Abstracts of Papers of the American Chemical Society: 236th National Meeting of the American Chemical Society. 2008, Philadelphia, Pennsylvania, USA: American Chemical Society.
• Calabrese C, Almassy R, Barton S, Batey M, Calvert AH, Canan-Koch S, Durkacz B, Hostomsky Z, Kumpf R, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford I, Skalitzky D, Thomas HD, Wang L, Webber S, William K, Curtin NJ. . Journal of the National Cancer Institute 2004, 96(1), 56-67.
• Newell DR, Silvester J, McDowell C, Burtles SS. . European Journal of Cancer 2004, 40(6), 899-906.
• Wells, P., Aboagye, E., Gunn, R., Osman, S., Boddy, A. V., Taylor, G. A., Rafi, I., Hughes, A. N., Calvert, A. H., Price, P., Newell, D. R. . Journal of the National Cancer Institute 2003, 95(9), 675-682.
• Davies T, Bentley J, Arris CE, Boyle FT, Curtin NJ, Endicott J, Gibson A, Golding BT, Griffin RJ, Hardcastle IR, Jewsbury, P., Johnson, L., Mesguiche, V., Newell, D.R., Noble, M., Tucker, J.A., Wang, L., Whitfield, H.J. . Nature Structural Biology 2002, 9(10), 745-749.
• Davies TG, Endicott JA, Noble ME, Johnson LN, Arris CE, Bentley J, Boyle FT, Calvert AH, Curtin NJ, Jewsberry PJ, Gibson AE, Golding BT, Griffin RJ, Hardcastle I, Mesguiche V, Parsons R, Whitfield H, Newell DR. . Cellular and Molecular Biology Letters 2001, 6(2B), 514-515.
• Davies TG, Endicott JA, Johnson LN, Noble ME, Arris CE, Bentley J, Calvert AH, Curtin NJ, Golding BT, Griffin RJ, Hardcastle IH, Mesguiche V, Newell H, Parsons RJ, Whitfield HJ, Boyle T, Jewsbury P. . Cellular and Molecular Biology Letters 2001, 6(2B), 470.
• Griffin RJ, Arris CE, Calvert AH, Curtin NJ, Jewsbury P, Endicott JA, Gibson AE, Boyle FT, Golding BT, Grant S, Johnson LN, Noble MEM, Newell DR, Lawrie A. . Abstracts of Papers of the American Chemical Society 2000, 219(2), U55 296-MEDI.
• Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Garman EF, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury P, Johnson LN, Lawrie AM, Newell DR, Noble MEM, Sausville EA, Schultz R, Yu W. . Journal of Medicinal Chemistry 2000, 43(15), 2797-2804.
• Bentley J, Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury PJ, Johnson LN, Noble MEM, Newell DR. . Clinical Cancer Research 2000, 6, 328.
• Matheson EC, Thomas H, Case M, Blair H, Jackson RK, Masic D, Veal G, Halsey C, Newell DR, Vormoor J, Irving JAE. . Haematologica 2019, 104(9), 1804-1811.
• Coxon RC, Wong C, Bayliss R, Boxall K, Carr KH, Fry AM, Hardcastle IR, Matheson CJ, Newell DR, Sivaprakasam M, Thomas H, Turner D, Yeoh S, Wang LZ, Griffin RJ, Golding BT, Cano C. . Oncotarget 2017, 8, 19089-19124.
• Drummond CJ, Esfandiari A, Liu J, Lu X, Hutton C, Jackson J, Bennaceur K, Xu Q, Makimanejavali AR, Bello FD, Piergentili A, Newell DR, Hardcastle IR, Griffin RJ, Lunec J. . Oncotarget 2016, 7(29), 46203-46218.
• Beale G, Haagensen E, Thomas H, Wang LZ, Revill C, Payne S, Golding BT, Hardcastle IR, Newell DR, Griffin RJ, Cano C. . British Journal of Cancer 2016, 115, 682-690.
• Reuillon T, Alhasan SF, Beale GS, Bertoli A, Brennan A, Cano C, Reeves HL, Newell DR, Golding BT, Miller DC, Griffin RJ. . Chemical Science 2016, 7(4), 2821-2826.
• Haagensen EJ, Thomas HD, Schmalix WA, Payne AC, Kevorkian L, Allen RA, Bevan P, Maxwell RJ, Newell DR. . Cancer Chemotherapy and Pharmacology 2016, 78(6), 1269-1281.
• Pearson RA, Thelwall PE, Snell J, McKenna J, Pieniazek P, Fitzgerald E, Heer R, McMenemin RM, Pedley ID, Azzabi A, Maxwell RJ, Newell DR, Plummer ER, Frew JA. . In: Genitourinary Cancers Symposium 2016. 2016, San Francisco, California: Journal of Clinical Oncology.
• Myers SM, Bawn RH, Bisset LC, Blackburn TJ, Cottyn B, Molyneux L, Wong AC, Cano C, Clegg W, Harrington RW, Leung H, Rigoreau L, Vidot S, Golding BT, Griffin RJ, Hammonds T, Newell DR, Hardcastle IR. . ACS Combinatorial Science 2016, 18(8), 444-455.
• Haagensen EJ, Thomas HD, Mudd C, Tsonou E, Wiggins CM, Maxwell RJ, Moore JD, Newell DR. . European Journal of Cancer 2016, 56, 69-76.
• Alhasan SF, Haugk B, Ogle LF, Beale GS, Long A, Burt AD, Tiniakos D, Televantou D, Coxon F, Newell DR, Charnley R, Reeves HL. . British Journal of Cancer 2016, 115(7), 797-804.
• Lochhead PA, Clark J, Wang LZ, Gilmour L, Squires M, Gilley R, Foxton C, Newell DR, Wedge SR, Cook SJ. . Cell Cycle 2016, 15(4), 506-518.
• Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, Televantou D, Thomas HD, Jackson J, Burt AD, Newell D, Rose J, Manas DM, Shapiro GI, Curtin NJ, Reeves HL. . Clinical Cancer Research 2015, 21(4), 925-933.
• Anscombe E, Meschini E, Mora-Vidal R, Martin MP, Staunton D, Geitmann M, Danielson UH, Stanley WA, Wang LZ, Reuillon T, Golding BT, Cano C, Newell DR, Noble MEM, Wedge SR, Endicott JA, Griffin RJ. . Chemistry & Biology 2015, 22(9), 1159-1164.
• Vormoor B, Schlosser Y, Blair H, Wilkinson S, Newell DR, Curtin N. . In: 47th Congress of the International Society of Paediatric Oncology (SIOP). 2015, Cape Town, South Africa: Wiley-Blackwell.
• Chen L, Rousseau RF, Middleton SA, Nichols GL, Newell DR, Lunec J, Tweddle DA. . Oncotarget 2015, 6(12), 10207-10221.
• Miller DC, Carbain B, Beale GS, Alhasan SF, Reeves HL, Baisch U, Newell DR, Golding BT, Griffin RJ. . Organic & Biomolecular Chemistry 2015, 13(18), 5279-5284.
• Zaytsev A, Dodd B, Magnani M, Ghiron C, Golding BT, Griffin RJ, Liu J, Lu X, Micco I, Newell DR, Padova A, Robertson G, Lunec J, Hardcastle IR. . Chemical Biology and Drug Discovery 2015, 86(2), 180-189.
• Evans L, Chen L, Milazzo G, Gherardi S, Perini G, Willmore E, Newell DR, Tweddle DA. . Cancer Letters 2015, 363(1), 37-45.
• Shouksmith AE, Evans LE, Tweddle DA, Miller DC, Willmore E, Newell DR, Golding BT, Griffin RJ. . Australian Journal of Chemistry 2015, 68(4), 660-679.
• Carbain B, Paterson DJ, Anscombe E, Campbell AJ, Cano C, Echalier A, Endicott JA, Golding BT, Haggerty K, Hardcastle IR, Jewsbury PJ, Newell DR, Noble MEM, Roche C, Wang LZ, Griffin RJ. . Journal of Medicinal Chemistry 2014, 57(1), 56-70.
• Anil B, Blackburn E, Blackburn T, Cully S, Liu J, Drummond CJ, Endicott JA, Golding BT, Griffin RJ, Haggerty K, Lunec J, Newell DR, Revill CH, Riedinger C, Watson AF, Xu Q, Zhao Y, Hardcastle IR, Noble MEM. . In: 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2014, Barcelona, Spain: Elsevier.
• Lebraud H, Golding BT, Meschini E, Cano C, Anscombe E, Wang LZ, Endicott JA, Noble MEM, Newell DR, Griffin RJ. . In: 247th ACS National Meeting and Exposition. 2014, Dallas, Texas: American Chemical Society.
• Shouksmith AE, Evans LE, Griffin RJ, Golding BT, Newell H, Miller DC, Noble MEM, Endicott JA, Tweddle D. . In: 247th ACS National Meeting and Exposition. 2014, Dallas, Texas: American Chemical Society.
• Myers S, Martin N, Bawn R, Blackburn T, Barrett L, Reuillon T, Golding B, Griffin R, Hammonds T, Hardcastle I, Leung H, Newell D, Rigoreau L, Wong A, Cano C. . In: 26th EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics. 2014, Barcelona, Spain: Elsevier.
• Pecqueur J, Vormoor B, Zhao Y, Newell H. . In: 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Theraputics. 2014, Barcelona, Spain: Elsevier.
• Martin M, Anscombe E, Meschini E, Staunton D, Geitmann M, Danielson UH, Wang LZ, Vidal RM, Reuillon T, Golding BT, Newell DR, Wedge S, Noble MEM, Endicott JA, Griffin RJ. . In: 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2014, Barcelona, Spain: Elsevier.
• Mould E, Berry P, Jamieson D, Hill C, Cano C, Tan N, Elliott S, Durkacz B, Newell D, Willmore E. . Biochemical Pharmacology 2014, 88(1), 58-65.
• Figg WD, Newell DR. . Clinical Cancer Research 2014, 20(10), 2525-2529.
• Tudhope S, Zhao Y, Wittner A, Wilmore E, Bertoli A, Adhikari S, Harnor SJ, Del Bello F, Piergentili A, Lunec J, Hardcastle IR, Griffin RJ, Golding BR, Cano C, Newell DR, Wedge SR. . In: AACR Annual Meeting 2014. 2014, San Diego, CA: American Association for Cancer Research.
• Chen L, Zhao Y, Halliday GC, Berry P, Rousseau RF, Middleton SA, Nichols GL, Del Bello F, Piergentili A, Newell DR, Lunec J, Tweddle DA. . British Journal of Cancer 2014, 111, 716-725.
• Harnor SJ, Rennison T, Galler M, Cano C, Griffin RJ, Newell DR, Golding BT. . MedChemComm 2014, 5(7), 984-988.
• Bertoli A, Adhikari S, Harnor SJ, Zhao Y, Lunec J, Wedge SR, Tudhope S, Wittner A, Golding BT, Hardcastle IR, Cano C, Newell DR, Griffin RJ. . In: 247th ACS National Meeting and Exposition. 2014, Dallas, TX, USA: American Chemical Society.
• Cano C, Saravanan K, Bailey C, Bardos J, Curtin NJ, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Menear KA, Newell DR, Richardson CJ, Shea K, Smith GCM, Thommes P, Ting A, Griffin RJ. . Journal of Medicinal Chemistry 2013, 56(16), 6386-6401.
• Barrett L, Rennison T, Clapham KM, Rodriguez-Aristegui S, Bardos J, Curtin NJ, Dennis M, Finlay R, Golding BT, Hardcastle IR, Newell DR, Young G, Cano C, Griffin RJ. . In: 245th ACS National Meeting and Exposition. 2013, New Orleans, Louisiana: American Chemical Society.
• Blackburn TJ, Ahmed S, Coxon CR, Liu JF, Lu XH, Golding BT, Griffin RJ, Hutton C, Newell DR, Ojo S, Watson AF, Zaytzev A, Zhao Y, Lunec J, Hardcastle IR. . MedChemComm 2013, 4(9), 1297-1304.
• Batey MA, Zhao Y, Kyle S, Richardson C, Slade A, Martin NMB, Lau A, Newell DR, Curtin NJ. . Molecular Cancer Therapeutics 2013, 12(6), 959-967.
• Cully SJ, Blackburn TJ, Cano C, Golding BT, Griffin RJ, Lunec J, Newell D, Noble M, Zhao Y, Hardcastle IR. . In: 245th ACS National Meeting and Exposition. 2013, New Orleans, Louisiana: American Chemical Society.
• Mould E, Berry P, Jamieson D, Hill C, Tan N, Elliott S, Durkacz B, Newell D, Willmore E. . In: American Association for Cancer Research 104th Annual Meeting. 2013, Washington, DC, USA: American Association for Cancer Research.
• Haagensen EJ, Thomas HD, Wilson I, Harnor SJ, Payne SL, Rennison T, Smith KM, Maxwell RJ, Newell DR. . PLoS ONE 2013, 8(12), e81763.